In Japan, though comprehensive genomic profiling can be conducted to test for somatic BRCA1/2 mutations, its wide application in clinical practice is hampered by its high cost and the reservation of testing in patients with primary ovarian cancer who cannot be treated with standard therapy. This evidence concerns the gene BRCA1 and ovarian carcinoma.